CHIP, ICUS, CCUS and other four-letter words

Leukemia

Volumn 31, Issue 9, 2017, Pages 1869-1871

  Bejar, R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLONE; CYTOPENIA; DNA SEQUENCE; DYSPLASIA; HEMATOPOIESIS; HUMAN; IDIOPATHIC DISEASE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; AGING; CELL CLONE; MUTATION; PATHOLOGY; PHYSIOLOGY; RISK ASSESSMENT;

AGING; CLONE CELLS; HEMATOPOIESIS; HUMANS; MUTATION; RISK ASSESSMENT;

EID: 85028863310     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2017.181     Document Type: Review

References (25)

1. Link DC, Walter MJ. 'CHIP'ping away at clonal hematopoiesis. Leukemia 2016; 30: 1633-1635.
2. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371: 2488-2498.
3. Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371: 2477-2487.
4. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014; 20: 1472-1478.
5. Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012; 44: 1179-1181.
6. Zink F, Stacey SN, Norddahl GL, Frigge ML, Magnusson OT, Jonsdottir I et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood 2017; e-pub ahead of print 8 may 2017; doi:10.1182/blood-2017-02-769869.
7. Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015 Jul 02; 126: 9-16.
8. Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: A case-control study. Lancet Oncol 2016; 18: 100-111.
9. Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: A proof-of-concept, case-control study. Lancet Oncol 2017; 18: 112-121.
10. Gibson CJ, Lindsley RC, Tchekmedyian V, Shi J, Mar BG, Jaiswal S et al. Clonal hematopoiesis associated with adverse outcomes following autologous stem cell transplantation for non-hodgkin lymphoma. Blood 2016; 128: 986-986.
11. Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 2015; 518: 552-555.
12. McKerrell T, Park N, Moreno T, Grove CS, Ponstingl H, Stephens J et al. Leukemiaassociated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep 2015; 10: 1239-1245.
13. Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-Associated mutations is ubiquitous in healthy adults. Nature Commun 2016; 7: 12484.
14. Yoshizato T, Dumitriu B, Hosokawa K, Makishima H, Yoshida K, Townsley D et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med 2015; 373: 35-47.
15. Stanley N, Olson TS, Babushok DV. Recent advances in understanding clonal haematopoiesis in aplastic anaemia. Br J Haematol 2017; 177: 509-525.
16. Kulasekararaj AG, Jiang J, Smith AE, Mohamedali AM, Mian S, Gandhi S et al. Somatic mutations identify a sub-group of aplastic anemia patients that progress to myelodysplastic syndrome. Blood 2014; 18: 2014-2005.
17. Ogawa S. Clonal hematopoiesis in acquired aplastic anemia. Blood 2016; 128: 337-347.
18. Valent P, Bain BJ, Bennett JM, Wimazal F, Sperr WR, Mufti G et al. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk Res 2012; 36: 1-5.
19. Kwok B, Hall JM, Witte JS, Xu Y, Reddy P, Lin K et al. MDS-Associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood 2015; 126: 2355-2361.
20. Cargo CA, Rowbotham N, Evans PA, Barrans SL, Bowen DT, Crouch S et al. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood 2015; 126: 2362-2365.
21. Kern W, Meggendorfer M, Haferlach C, Haferlach T. Integrated diagnostic approach for suspected myelodysplastic syndrome as a basis for advancement of diagnostic criteria. Blood 2016; 128: 299-299.
22. Malcovati L, Gall A, Travaglino E, Ambaglio I, Rizzo E, Molteni E et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood 2017; e-pub ahead of print 19 April 2017; doi:10.1182/blood-2017-01-763425.
23. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328-333.
24. Wong TN, Miller CA, Klco JM, Petti A, Demeter R, Helton NM et al. Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood 2016; 127: 893-897.
25. Thol F, Klesse S, Kohler L, Gabdoulline R, Kloos A, Liebich A et al. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis. Leukemia 2017; 31: 1286-1295.